Antigen details
Reactivity & Specifity: CD5 is present on all mature T cells and most thymocytes. It is also expressed on a small subpopulation of normal B cells. The majority of T- cell malignancies (76%) express CD5, and almost 85% of T- cell acute lymphoblastic leukaemias are CD5 positive.
The reactivity of LT-20 MoAb has a bit wide including some dendritic cells, endothelial cells on vessels epithelial cells, some macrophages and some activated T cells. CD20 antigen is present on 8-16% of normal peripheral blood lymphocytes. CD20 MoAb recognizes? type III unglycosylated phosphoprotein which crosses the cell membrane four times called TM4.
Clinical Application: Further, CD5 is expressed in some B- cell derived lymphoproliferative disorders, notably chronic lymphocytic leukaemia (CLL) (> 90%) (1, 2), and centrocytic leukaemia.CD20 can be considered a pan- B cell antigen, as it is expressed on the surface of all mature B lymphocytes but not in secreting plasma cells. CD20 is expressed early during pre- B cell development, presumably just before the expression of cytoplasmic μ- chains, and it persists until plasma cell differentiation. A small subset of T cells expresses low levels of CD20. CD20 is expressed in acute lymphoblastic leukaemia, B- cell chronic lymphocyticleukaemia, hairy cell leukaemia and Burkitt’s lymphoma.
